Immunome Inc (NASDAQ: IMNM) is -26.20% lower on its value in year-to-date trading and has touched a low of $5.15 and a high of $16.81 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IMNM stock was last observed hovering at around $9.67 in the last trading session, with the day’s gains setting it 0.78%.
Currently trading at $10.45, the stock is 17.77% and 20.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing 8.07% at the moment leaves the stock 4.87% off its SMA200. IMNM registered -1.60% loss for a year compared to 6-month gain of 11.41%. The firm has a 50-day simple moving average (SMA 50) of $8.6608 and a 200-day simple moving average (SMA200) of $10.0386.
The stock witnessed a 9.54% loss in the last 1 month and extending the period to 3 months gives it a 41.22%, and is 16.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.58% over the week and 6.31% over the month.
Immunome Inc (IMNM) has around 118 employees, a market worth around $909.28M and $10.94M in sales. Profit margin for the company is -1875.21%. Distance from 52-week low is 102.91% and -37.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.76%).
The EPS is expected to grow by 56.81% this year
200.0 institutions hold shares in Immunome Inc (IMNM), with institutional investors hold 94.07% of the company’s shares. The shares outstanding are 86.96M, and float is at 76.80M with Short Float at 16.38%. Institutions hold 83.28% of the Float.
The top institutional shareholder in the company is REDMILE GROUP, LLC with over 4.89 million shares valued at $59.16 million. The investor’s holdings represent 8.1579 of the IMNM Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 4.21 million shares valued at $50.95 million to account for 7.0257 of the shares outstanding. The other top investors are ECOR1 CAPITAL, LLC which holds 3.88 million shares representing 6.4725 and valued at over $46.94 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 6.4712 of the shares totaling 3.88 million with a market value of $46.93 million.
Immunome Inc (IMNM) Insider Activity
The most recent transaction is an insider purchase by BIENAIME JEAN JACQUES, the company’s Director. SEC filings show that BIENAIME JEAN JACQUES bought 5,000 shares of the company’s common stock on Jun 03 ’25 at a price of $9.38 per share for a total of $46900.0. Following the purchase, the insider now owns 36415.0 shares.
Immunome Inc disclosed in a document filed with the SEC on Mar 25 ’25 that BIENAIME JEAN JACQUES (Director) bought a total of 7,800 shares of the company’s common stock. The trade occurred on Mar 25 ’25 and was made at $7.78 per share for $60684.0. Following the transaction, the insider now directly holds 31415.0 shares of the IMNM stock.
Still, SEC filings show that on Mar 26 ’25, SIEGALL CLAY B (President and CEO) acquired 137,100 shares at an average price of $7.29 for $1.0 million. The insider now directly holds 806,736 shares of Immunome Inc (IMNM).
